Hypertension
Cohort Study | Visit-to-visit SBP variability linked to increased risk of atrial fibrillation in middle-aged and older populations.
17 Oct, 2022 | 12:30h | UTC
Position Statement | Home blood pressure monitoring.
14 Oct, 2022 | 14:16h | UTCRelated:
RCT | No difference in cardiovascular outcomes with evening vs. morning dosing of usual antihypertensives.
12 Oct, 2022 | 14:01h | UTCRelated Consensus Statement: Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension – Journal of Hypertension
Related study (conflicting results): Bedtime Hypertension Treatment Improves Cardiovascular Risk Reduction in Randomized Trial
Perspective | Hydrochlorothiazide vs. chlorthalidone – what is the difference?
11 Oct, 2022 | 13:40h | UTCHydrochlorothiazide Versus Chlorthalidone–What is the Difference? – Circulation (free for a limited period)
Related:
Meta-analysis: Chlorthalidone vs. hydrochlorothiazide
Commentary on Twitter
There are big differences among diuretics even within the same class. So let us rethink the class effect. https://t.co/ruE4IYeFf2. Here I discuss what we know about HCTZ vs CTD. pic.twitter.com/cyljdi04v9
— Rajiv Agarwal MD, MS (@AgarwalRajivMD) October 8, 2022
RCT | Intrapartum extended-release nifedipine to prevent severe intrapartum hypertension in patients with severe preeclampsia.
4 Oct, 2022 | 14:37h | UTCTrial of Intrapartum Extended-Release Nifedipine to Prevent Severe Hypertension Among Pregnant Individuals With Preeclampsia With Severe Features – Hypertension (link to abstract – $ for full-text)
News Release: Severe preeclampsia treated safely with nifedipine during labor and delivery – American Heart Association
ESC Scientific Statement | Sex differences in arterial hypertension.
26 Sep, 2022 | 12:10h | UTC
Commentary on Twitter
Terrific work on this important statement on #sexdifferences in #hypertension @EvaGerdts @AnastasiaSMihai @MaasAngela et al! 👏🏽https://t.co/jhTXP0NTqJ pic.twitter.com/VBkbKLyV5K
— Dr. Martha Gulati ♥️🫀❤️🩹🇨🇦 (@DrMarthaGulati) September 23, 2022
Under a https://creativecommons.org/licenses/by-nc/4.0/ license
Long-term follow-up of a RCT | Outcomes after catheter-based renal artery denervation for resistant hypertension.
20 Sep, 2022 | 13:33h | UTCLong-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial – The Lancet (free registration required)
Commentary: SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss – TCTMD
Original Study: A Controlled Trial of Renal Denervation for Resistant Hypertension – New England Journal of Medicine
Nonadherence was revealed through measurements of serum concentrations of antihypertensive drugs in one-third of patients with resistant hypertension previously evaluated as adherent.
11 Sep, 2022 | 22:35h | UTC
Review | The management of hypertensive emergencies—is there a “magical” prescription for all?
8 Sep, 2022 | 14:32h | UTC
Review/Perspective | European hypertension guideline downgrading of beta-blockers is not justified.
31 Aug, 2022 | 11:51h | UTC
Salt substitutes vs. regular salt: a quick look.
30 Aug, 2022 | 12:02h | UTCSalt substitutes vs. regular salt: a quick look – Evidently Cochrane
Original Study: Replacing salt with low‐sodium salt substitutes (LSSS) for cardiovascular health in adults, children and pregnant women – Cochrane Library
Related:
Effects of salt substitutes on clinical outcomes: a systematic review and meta-analysis – Heart (link to abstract – $ for full-text)
RCT: Reduced-sodium added-potassium salt substitute reduces blood pressure in hypertensive patients
Potassium Enriched Salt Substitution Could Prevent a Large Number of Cardiovascular Deaths
Commentary on Twitter
https://twitter.com/CochraneLibrary/status/1563130897159028737
M-A | Urban-rural differences in hypertension prevalence in low-income and middle-income countries, 1990–2020.
30 Aug, 2022 | 11:55h | UTCNews Release: Study shows urban-rural differences in hypertension prevalence in low-income and middle-income countries – News Medical
Commentary on Twitter
🚨paper alert! In LMICs, is #hypertension more prevalent in urban or rural areas?
Nearly 300 studies from 66 LMICs (>19 million participants) revealed that the rate of change from 1990-2022 appears greater in rural.
It has been so nice contributing to this tremendous work!🤩 https://t.co/EjbRpf83HJ
— Adna Curto (@adna_otti) August 27, 2022
Study shows an increasing incidence of hypertensive disorders in pregnancy.
30 Aug, 2022 | 11:52h | UTCCommentaries:
Increased incidence of hypertensive disorders of pregnancy in young Americans – News Medical
Hypertensive Disorders in Pregnancy on the Rise – AJMC
Commentary on Twitter
Independent birth cohort effect on rates of hypertensive disorders of pregnancy higher incidence in younger generations and persistent racial and ethnic disparities. Increased awareness even among young pregnant people is needed. #OAResearch https://t.co/wNwIZTYLHZ
— JAMA Network Open (@JAMANetworkOpen) August 24, 2022
[News release – not published yet] #ESCCongres – RCT | Evening dosing of blood pressure medication not better than morning dosing.
29 Aug, 2022 | 12:30h | UTCRelated Consensus Statement: Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension – Journal of Hypertension
Related study (conflicting results): Bedtime Hypertension Treatment Improves Cardiovascular Risk Reduction in Randomized Trial
Bedtime dosing of antihypertensive medications: systematic review and consensus statement. – “use of bedtime drug dosing of antihypertensive drugs should not be routinely recommended”.
29 Aug, 2022 | 12:28h | UTC
RCT | Self-measurement of blood pressure with a standard device is not enhanced by the use of a connected smartphone application.
26 Aug, 2022 | 13:29h | UTCEffectiveness of Standard vs Enhanced Self-measurement of Blood Pressure Paired With a Connected Smartphone Application: A Randomized Clinical Trial – JAMA Internal Medicine (link to abstract – $ for full-text)
News Release: For Checking Blood Pressure at Home, Basic Cuffs Are Just as Good – UC San Francisco
Commentary: App-enabled device no better than standard device for self-measuring blood pressure – ACP Internist
Commentary on Twitter
Monitoring #bloodpressure at home may help with #bloodpressurecontrol, but using an enhanced device pairing with a smartphone application appears to be no more effective than using a standard device. https://t.co/h6zREImCNv #Research pic.twitter.com/T1zWDlp2pC
— JAMA Internal Medicine (@JAMAInternalMed) August 15, 2022
Cross-Sectional Study | Hypertension common among poorest, least educated around the world.
22 Aug, 2022 | 12:14h | UTCThe Association of Socioeconomic Status With Hypertension in 76 Low- and Middle-Income Countries – Journal of the American College of Cardiology (link to abstract – $ for full-text)
News Release: Hypertension Common Among Poorest, Least Educated Around the World – American College of Cardiology
Commentary: Hypertension Common Among Poorest, Least Educated Globally – HealthDay
Commentary on Twitter
#HTN is a common condition in low- & middle-income countries. As countries develop economically, these groups may experience a greater #hypertension prevalence relative to those w/ ⬆️ socioeconomic status. Read more on this important work now out in #JACC: https://t.co/sOzb1aWRvk pic.twitter.com/w00raCmuCW
— JACC Journals (@JACCJournals) August 16, 2022
Cohort Study | Aldosterone linked to increased risk of chronic kidney disease progression and end-stage kidney disease.
19 Aug, 2022 | 16:09h | UTCOriginal Study: Aldosterone in chronic kidney disease and renal outcomes – European Heart Journal
Editorial: Aldosterone excess and cardiorenal risk: more common than appreciated – European Heart Journal
Commentary on Twitter
https://twitter.com/ESC_Journals/status/1556898902258991104
M-A | Performance of confirmatory tests for diagnosing primary aldosteronism.
18 Aug, 2022 | 12:54h | UTC
Commentary on Twitter
https://twitter.com/HyperAHA/status/1559624529869160448
Modeling Study | Reducing daily salt intake in China by 1 g could prevent almost 9 million cardiovascular events by 2030.
18 Aug, 2022 | 12:42h | UTCNews Release: 1 g cut in daily salt intake could ward off nearly 9 million cases of stroke/heart disease in China – BMJ Newsroom
Harmonization of American and European hypertension guidelines: comparisons, reflections, and recommendations.
12 Aug, 2022 | 15:19h | UTCHarmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines: Comparisons, Reflections, and Recommendations – European Heart Journal (also available at Circulation)
Systematic Review | Replacing salt with low‐sodium salt substitutes for cardiovascular health in adults, children and pregnant women.
10 Aug, 2022 | 15:38h | UTCRelated:
Effects of salt substitutes on clinical outcomes: a systematic review and meta-analysis – Heart
RCT: Reduced-sodium added-potassium salt substitute reduces blood pressure in hypertensive patients
Potassium Enriched Salt Substitution Could Prevent a Large Number of Cardiovascular Deaths
M-A | Effects of salt substitutes on clinical outcomes.
10 Aug, 2022 | 15:40h | UTCEffects of salt substitutes on clinical outcomes: a systematic review and meta-analysis – Heart
Commentary: Swapping salt for substitutes reduces risk of stroke and heart conditions – study – The Guardian
Related:
RCT: Reduced-sodium added-potassium salt substitute reduces blood pressure in hypertensive patients
Potassium Enriched Salt Substitution Could Prevent a Large Number of Cardiovascular Deaths
Commentary from the author on Twitter
Our latest meta-analysis shows consistent effects of salt substitutes on BP across diverse geographies and populations. Protective effects on clinical outcomes are likely to be generalizable to countries worldwide. https://t.co/C273yK6Bek
— Xuejun Yin (@XuejunYin) August 10, 2022
M-A | Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes.
29 Jul, 2022 | 12:37h | UTCCommentaries:
No justification for bespoke antihypertensive intervention in type 2 diabetes – medwire News
Blood pressure control according to type 2 diabetes status – The Lancet Diabetes & Endocrinology (free registration required)
Commentary on Twitter
Online—Blood pressure-lowering treatment for prevention of major #cardiovascular diseases in people with and without type 2 #diabetes: an individual participant-level data meta-analysis https://t.co/AmNxyW9Via #T2D #BloodPressure #hypertension #openaccess pic.twitter.com/NfdLktZXai
— The Lancet Diabetes & Endocrinology (@TheLancetEndo) July 25, 2022
Systematic Review | Antiplatelet agents and anticoagulants for hypertension.
29 Jul, 2022 | 12:29h | UTCAntiplatelet agents and anticoagulants for hypertension – Cochrane Library
Summary: Antiplatelet agents and anticoagulants for high blood pressure – Cochrane Library
Commentary on Twitter
Do #antiplatelet agents & #anticoagulants improve outcomes in people with #hypertension?
Our newly updated @CochraneLibrary review looks at the evidence of 6 RCTs involving more than 61,000 participants: https://t.co/zaXP4YLg4n#CochraneEvidence #blogshot pic.twitter.com/X1DK2NTCtb
— Cochrane Hypertension (@CochraneHTN) July 28, 2022